IL-1β, IL-1 receptor antagonist and soluble type II IL-1 receptor in synovial fluid of patients with temporomandibular disorders

Archives of Oral Biology

Volumn 49, Issue 6, 2004, Pages 493-499

  Tominaga, Kazuhiro ^a   Habu, Manabu ^a   Sukedai, Miho ^a   Hirota, Yuriko ^a   Takahashi, Tetsu ^a   Fukuda, Jinichi ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Interleukin 1 receptor; Interleukin 1 receptor antagonist; Interleukin 1 ; Temporomandibular disorder

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR TYPE II;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDER;

ADOLESCENT; ADULT; AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-1; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-1 TYPE II; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS;

EID: 16544377551     PISSN: 00039969     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archoralbio.2003.12.008     Document Type: Article

References (29)

1. Arend W.P. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthrit Rheum. 30(Suppl 2):2001;1-6.
2. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol. 22:2001;328-336.
3. Arend W.P., Malyak M., Smith M.F.et al. Binding of IL-1α, IL-1β, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. J Immunol. 153:1994;4766-4774.
4. Alstergren P., Ernberg M., Kvarnstrom M., Kopp S. interleukin-1β in synovial fluid from the arthritic temporomandibular joint and its relation to pain, mobility and anterior open bite. J Oral Maxillofac Surg. 56:1998;1059-1065.
5. Kubota E., Imamura H., Kubota T., Shibata T., Murakami K. Interleukin-1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg. 55:1997;20-27.
6. Kubota E., Kubota T., Matsumoto J., Shibata T., Murakami K. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg. 56:1998;192-198.
7. Takahashi T., Kondoh T., Fukuda M., Yamazaki Y., Toyosaki T., Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 85:1998;135-141.
8. Alstergren P., Benavente P., Kopp C. Interleukin-1, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac. Surg. 61:2003;1171-1178.
9. Alstergren P., Appelgren A., Appelgren B., Kopp S., Lundeberg T., Theodorsson E. Determination of temporomandibular joint fluid concentrations using vitamin B12 as an internal standard. Eur J Oral Sci. 103:1995;214-218.
10. Miossec P. Role of interleukin-1 in the pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol. 5:1987;305-308.
11. Rooney M., Symons J.A., Duff G.W. Interleukin 1 beta in synovial fluid is related to local disease activity in rheumatoid arthritis. Rheumatol Int. 10:1990;217-219.
12. Suzuki T., Segami N., Kaneyama K., Nishimura M., Nojima T. Specific expression of interleukin-1β in temporomandibular joints with internal derangement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 88:1999;413-417.
13. Shibata T., Murakami K., Kubota E., Maeda H. Glycosaminoglycan components in temporomandibular joint synovial fluid as markers of joint pathology. J Oral Maxillofac Surg. 56:1998;209-213.
14. Kaneyama K., Segami N., Nishimura M., Sato J., Suzuki T., Fujimura K. Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. Int J Oral Maxillofac Surg. 32:2003;404-407.
15. Habu M., Tominaga K., Sukedai M.et al. Immunohistochemical study of interleukin-1β and interleukin-1 receptor antagonist in an antigen-induced arthritis of the rabbit temporomandibular joint. J Oral Pathol Med. 31:2002;45-54.
16. Firestein G.S., Boyle D.L., Yu C.et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37:1994;644-652.
17. Chomarat P., Vannier E., Dechanet J.et al. The balance of IL-1receptor antagonist/IL-1b in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol. 154:1995;1432-1439.
18. Shingu M., Fujikawa Y., Wada T., Nonaka S., Nobunaga M. Increased IL-1 receptor antagonist (IL-1ra) production and decreased IL-1 beta/IL-1ra ratio in mononuclear cells from rheumatoid arthritis patients. Br J Rheumatol. 34:1995;24-30.
19. Ma Y., Thornton S., Boivin G.P., Hirsch D., Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum. 41:1998;1798-1805.
20. Horai R., Saijo S., Tanioka H.et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med. 191:2000;313-320.
21. Jouvenne P., Vannier E., Dinarello C.A., Miossec P. Elevated levels of soluble interleukin-1 receptor type II and interleukin-1 receptor antagonist in patients with chronic arthritis. Arthritis Rheum. 41:1998;1083-1089.
22. Colotta F., Saccani S., Giri J.G.et al. Regulated expression and release of the interleukin-1 decoy receptor in human mononuclear phagocytes. J Immunol. 156:1996;2534-2541.
23. Colotta F., Re F., Muzio M.et al. Interleukin-1 typeII receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 261:1993;472-475.
24. Colotta F., Re F., Muzio M.et al. Interleukin-13 induces expression and release of the interleukin-1 decoy receptor in human polymorphonuclear cells. J Biol Chem. 269:1994;12403-12406.
25. Orlando S., Polentarutti N., Mantovani A. Selectivity release of the type II decoy IL-1 receptor. Cytokine. 12:2000;1001-1006.
26. Colotta F., Orlando S., Fadlon E.J., Sozzani S., Matteucci C., Mantovani A. Chemoattractants induce rapid release of the interleukin-1 type II decoy receptor in human polymorphonuclear cells. J Exp Med. 181:1995;2181-2188.
27. Orlando S., Matteucci C., Fadlon E.J.et al. TNF-α, unlike other pro- and anti-inflammatory cytokines, induces rapid release of the IL-1 type II decoy receptor in human myelomonocytic cells. J Immunol. 158:1997;3861-3868.
28. Penton-Rol G., Orlando S., Polentarutti N., Bernasconi S., Muzio M., Introna M. Bacterial lipopolysaccharide causes rapid shedding, followed by inhibition of mRNA expression, of the IL-1 type II receptor, with concomitant up-regulation of the type I receptor and induction of incompletely spliced transcripts. J Immunol. 162:1999;2931-2938.
29. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood. 87:1996;2095-2147.